You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
百奧賽圖遞表港交所IPO申請
格隆匯8月30日丨據港交所文件顯示,百奧賽圖已遞交上市申請,高盛、中金爲聯席保薦人。 百奧賽圖是臨牀階段生物技術及臨牀前研究服務創收公司,以高通量體內抗體發現平臺、專有基因編輯技術、轉基因小鼠平臺以及綜合動物病患模型爲依託。百奧賽圖發起的全球首個大規模體內抗體發現篩選計劃“千鼠萬抗”有望成爲大量同類首創抗體或者針對新型及/或困難藥物靶點的同類最佳抗體的起源,並加速推進臨牀開發。百奧賽圖建立了12個研發產品的豐富研發管線,其中4個抗體分子進入臨牀階段(2個全球臨牀II期,2個臨牀I期),6個產品處於臨牀前階段,並對外授權/合作2個抗體分子。百奧賽圖開發了轉基因RenMice平臺(其中包括了兩個全人源轉基因小鼠平臺RenMab和RenLite),能生成豐富的全人源單克隆抗體庫及多特異性抗體庫。根據弗若斯特沙利文,百奧賽圖的RenMab平臺是全球頂級原位置換技術全人源轉基因小鼠抗體生成平臺之一。百奧賽圖爲製藥和生物技術公司提供基因編輯、臨牀前藥理藥效評價、動物模型銷售及抗體研發等服務和研發合作。2020年服務於全球近800家客戶,海外銷售收入佔比超過36%。百奧賽圖與全球10家大型製藥企業中的8家建立長期的合作關係。(格隆匯)
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account